Profile data is unavailable for this security.
About the company
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.
- Revenue in HKD (TTM)7.14bn
- Net income in HKD772.50m
- Incorporated2015
- Employees7.03k
- LocationSimcere Pharmaceutical Group LtdNo. 699-18Xuanwu Avenue, Xuanwu DistrictNANJING ChinaCHN
- Websitehttp://www.simcere.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AIM Vaccine Co Ltd | 1.28bn | -1.41bn | 9.72bn | 1.62k | -- | 2.47 | -- | 7.58 | -1.16 | -1.16 | 1.06 | 3.25 | -- | -- | -- | 790,268.00 | -- | -- | -- | -- | 75.88 | -- | -164.24 | -- | 0.7583 | -14.04 | 0.3158 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
Shanghai Henlius Biotech Inc | 5.83bn | 590.13m | 9.77bn | 3.64k | 16.61 | 4.12 | 9.99 | 1.68 | 1.08 | 1.08 | 10.68 | 4.36 | 0.5731 | 1.95 | 9.10 | 1,603,169.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
Yichang Hec Changjiang Pharmactcl Co Ltd | 6.80bn | 2.15bn | 9.91bn | 4.62k | 4.60 | 1.16 | 4.08 | 1.46 | 2.45 | 2.45 | 7.73 | 9.75 | 0.5111 | 3.62 | 4.09 | 1,473,166.00 | 15.07 | 8.03 | 24.46 | 11.81 | 79.21 | 79.97 | 29.48 | 20.80 | 1.30 | 11.16 | 0.2475 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
InnoCare Pharma Ltd | 798.20m | -682.26m | 10.00bn | 1.09k | -- | 1.16 | -- | 12.52 | -0.4045 | -0.4045 | 0.473 | 4.38 | 0.073 | 1.39 | 3.39 | 732,964.40 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
Keymed Biosciences Inc | 382.70m | -388.39m | 10.53bn | 897.00 | -- | 3.26 | -- | 27.52 | -1.49 | -1.49 | 1.45 | 11.54 | 0.0906 | 0.7314 | 26.14 | 426,644.20 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
Luye Pharma Group Ltd | 6.64bn | 575.63m | 11.25bn | 5.27k | 19.44 | 0.8305 | 8.39 | 1.69 | 0.1538 | 0.1538 | 1.78 | 3.60 | 0.247 | 2.42 | 3.60 | 1,259,836.00 | 2.17 | 2.80 | 3.56 | 4.45 | 68.44 | 70.53 | 8.78 | 10.39 | 1.21 | 3.10 | 0.3931 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
SciClone Pharmaceuticals (Holdings) Ltd | 3.41bn | 1.21bn | 11.48bn | 1.05k | 9.81 | 3.12 | 8.38 | 3.37 | 1.86 | 1.86 | 5.24 | 5.84 | 0.7585 | 3.56 | 3.83 | 3,248,128.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 33.70 | 0.01 | 22.98 | 14.76 | 17.50 | 31.16 | 15.96 | 25.65 | -- |
SSY Group Ltd | 6.46bn | 1.32bn | 14.37bn | 5.60k | 10.93 | 2.07 | 8.22 | 2.22 | 0.4427 | 0.4427 | 2.17 | 2.33 | 0.5637 | 3.00 | 3.01 | 1,154,109.00 | 11.59 | 10.51 | 15.58 | 14.03 | 56.01 | 58.72 | 20.57 | 18.62 | 1.60 | 29.61 | 0.317 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
Simcere Pharmaceutical Group Ltd | 7.14bn | 772.50m | 15.01bn | 7.03k | 19.84 | 1.93 | 13.57 | 2.10 | 0.2898 | 0.2898 | 2.74 | 2.98 | 0.6106 | 3.53 | 2.65 | 1,016,309.00 | 6.60 | 10.17 | 8.94 | 15.60 | 75.43 | 78.82 | 10.80 | 17.50 | 1.87 | 0.9742 | 0.1652 | 46.68 | 4.49 | 7.92 | -23.22 | -0.5213 | 23.93 | -- |
Zai Lab Ltd | 2.27bn | -2.64bn | 15.38bn | 2.18k | -- | 2.54 | -- | 6.77 | -2.73 | -2.73 | 2.34 | 6.11 | 0.2697 | 2.84 | 5.61 | -- | -31.41 | -37.72 | -36.81 | -42.72 | 62.86 | 64.75 | -116.45 | -282.44 | 4.43 | -- | 0.0596 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
3SBio Inc | 8.45bn | 1.67bn | 15.49bn | 5.41k | 9.41 | 1.00 | 7.46 | 1.83 | 0.6748 | 0.6748 | 3.46 | 6.32 | 0.3426 | 1.58 | 7.01 | 1,561,141.00 | 6.95 | 7.44 | 9.03 | 9.29 | 84.98 | 82.91 | 20.30 | 21.50 | 2.26 | 22.72 | 0.2266 | -- | 13.84 | 11.26 | -19.13 | 3.94 | 8.78 | -- |
Grand Pharmaceutical Group Ltd | 10.53bn | 1.88bn | 18.17bn | 10.53k | 9.56 | 1.18 | 7.94 | 1.73 | 0.5356 | 0.5356 | 3.00 | 4.33 | 0.4692 | 2.94 | 10.26 | 999,581.40 | 8.45 | 10.09 | 11.66 | 14.01 | 61.96 | 61.97 | 18.00 | 22.35 | 0.9819 | 22.96 | 0.1831 | 26.94 | 10.12 | 12.06 | -9.59 | 21.41 | 5.69 | 24.77 |
The United Laboratories Intl. Hldgs Ltd. | 14.85bn | 2.92bn | 18.35bn | 15.00k | 6.29 | 1.33 | 5.20 | 1.24 | 1.61 | 1.61 | 8.17 | 7.57 | 0.6871 | 3.36 | 6.15 | 989,988.60 | 13.51 | 7.89 | 20.52 | 12.64 | 46.11 | 44.17 | 19.66 | 12.73 | 1.74 | -- | 0.1055 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 14.67 |
Data as of May 17 2024. Currency figures normalised to Simcere Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 46.12m | 1.77% |
Norges Bank Investment Managementas of 31 Dec 2023 | 24.51m | 0.94% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 18.65m | 0.72% |
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 18.48m | 0.71% |
Essence Fund Co., Ltd.as of 30 Jun 2023 | 14.74m | 0.57% |
Principal Global Investors (Hong Kong) Ltd.as of 30 Jun 2023 | 14.12m | 0.54% |
China Asset Management Co., Ltd.as of 30 Jun 2023 | 10.05m | 0.39% |
Dimensional Fund Advisors LPas of 04 Apr 2024 | 9.82m | 0.38% |
Huashang Fund Management Co., Ltd.as of 30 Jun 2023 | 7.20m | 0.28% |
First Seafront Fund Management Co., Ltd.as of 30 Jun 2023 | 6.72m | 0.26% |
More ▼
Data from 30 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.